248 related articles for article (PubMed ID: 35641860)
1. A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus.
Askanase AD; Furie RA
Adv Ther; 2022 Jul; 39(7):3088-3103. PubMed ID: 35641860
[TBL] [Abstract][Full Text] [Related]
2. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
3. Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.
Girman C; Panaccio MP; Hayes K; Niewoehner J; Wan GJ
Adv Ther; 2022 Jul; 39(7):3072-3087. PubMed ID: 35635646
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
[TBL] [Abstract][Full Text] [Related]
5. Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Askanase AD; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2020 Dec; 7(4):893-908. PubMed ID: 32996096
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
7. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
8. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus.
Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383
[TBL] [Abstract][Full Text] [Related]
10. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
[TBL] [Abstract][Full Text] [Related]
11. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
Wan GJ; Niewoehner J; Hayes K
Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study.
Furie R; Mitrane M; Zhao E; Das M; Li D; Becker PM
Lupus Sci Med; 2016; 3(1):e000180. PubMed ID: 27933199
[TBL] [Abstract][Full Text] [Related]
13. Real-World Treatment Patterns and Outcomes from an Electronic Medical Records Database for Patients with Rheumatoid Arthritis Treated with Repository Corticotropin Injection.
Hayes K; Panaccio MP; Houston P; Niewoehner J; Fahim M; Wan GJ; Dhillon B
Open Access Rheumatol; 2021; 13():315-323. PubMed ID: 34703332
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
Drugs Context; 2022; 11():. PubMed ID: 35382109
[TBL] [Abstract][Full Text] [Related]
15. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
Furie RA; Mitrane M; Zhao E; Becker PM
Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
[TBL] [Abstract][Full Text] [Related]
16. Acthar
Kaplan J; Askanase A; Chu D; Abdellatif A; Basu D; Mirsaeidi M
Clin Drug Investig; 2023 Oct; 43(10):739-761. PubMed ID: 37792273
[TBL] [Abstract][Full Text] [Related]
17. Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review.
Mirsaeidi M; Baughman RP
Pulm Ther; 2022 Mar; 8(1):43-55. PubMed ID: 35113366
[TBL] [Abstract][Full Text] [Related]
18. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.
Ho-Mahler N; Turner B; Eaddy M; Hanke ML; Nelson WW
Open Access Rheumatol; 2020; 12():21-28. PubMed ID: 32110122
[TBL] [Abstract][Full Text] [Related]
20. A Narrative Review of Acthar Gel for the Treatment of Myositis.
Chandra T; Aggarwal R
Rheumatol Ther; 2023 Jun; 10(3):523-537. PubMed ID: 36966453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
